title: Accrual to cancer clinical trials in the era of molecular medicine.
abstract: Enrollment of patients in a clinical trial is difficult as a result of a host of well-documented barriers. In the field of oncology, molecularly targeted treatments have demonstrated considerable therapeutic promise. At the same time, clinical testing of these targeted agents has introduced new complexities in the decision-making process by patients or providers on whether to participate in clinical trials. Explored in this Commentary are challenges of and potential solutions for the clinical testing of modern cancer therapies.
authors: Section of Hematology-Oncology and Comprehensive Cancer Center, University of Chicago, Chicago, IL 60637, USA. rschilsk@medicine.bsd.uchicago.edu
authors: Richard L
authors: RL
authors: Schilsky
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D008967:Molecular Biology; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D010358:Patient Participation; D018579:Patient Selection; D010817:Physician-Patient Relations